A prospective study evaluating the efficacy of 18F-PSMA PET/CT combined with PET/MR in the diagnosis of clinically significant prostate cancer: comparing prostate biopsy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062341

Enrollment

Unknown

Registered

2022-08-02

Start date

2022-08-03

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinically significant prostate cancer

Interventions

Gold Standard:Pathological results of prostatic systemic puncture and targeted puncture

Index test:18F-PSMA&#32

PET/CT,18F-PSMA&#32

PET/MR

Eligibility

Sex/Gender

Male

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Subjects aged 30-85 years old; (2) Clinically significant prostate cancer patients: 1. Patients with dysuria, frequency of urination, urgency of urination and other clinical manifestations; 2. patients with serum prostate specific antigen (PSA) higher than the normal range; 3. patients with hard prostate nodules found on digital rectal examination; (3) patients who planned to undergo prostate puncture; (4) patients voluntarily participated in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with mri contraindications; (2) patients with severe cardiopulmonary diseases; (3) patients deemed unsuitable for the study according to the investigator's judgment.

Design outcomes

Primary

Measure	Time frame
SUVmax;SUVmean;PSMA-MTV;	—

Countries

China

Contacts

Public ContactGuangjie Yang

ygj_2815@qq.com+86 17853297979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026